Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

@maiti_86 @midorinoaojiru 抗体価が長期間維持されることがそんなに珍しいことなのかと思って、他のワクチンを見てみたのですが、アストラゼネカのアデノベクター型ワクチンでは84日まで高いままのようです。 https://t.co/44bNIAEMfz https://t.co/TchpcRJmXs

@Krypton38092061 @EinTyp15496172 @SteffenBorucki @Barbara40008922 @RobertBoni6 https://t.co/Cyb36e0UF0

@Grievous108 https://t.co/rMdMx2FOVX https://t.co/QrOJY9KnZk https://t.co/hDiv7ByKeM https://t.co/ivEvZQxDgi https://t.co/GoIhqpuneO https://t.co/WorC0CdKGX

@FourWinns298 @lisa_iannattone Dec 2020: ‘Following a trial amendment on 22 June 2020, 52 participants aged between 18 and 55 years, who had already received an initial standard dose of ChAdOx1 nCoV-19, were boosted with a second dose of ChAdOx1 nCoV-19 …

@VikiLovesFACS So if you are comfortable with your risk you can delay the shot knowing you have both arms of the immune system activated..OR you can take the booster knowing that is better tolerated than the priming dose. https://t.co/kJXJ9ttFR4

@C3_Nik @Karl_Lauterbach The studies have shown that using a lower second dose results in lesser response: https://t.co/kkTUtIWNYW By extrapolation, halving both doses would probably go further in the same direction (less efficacy)

@DavidLevan15 @SandraWeeden "Antibodies against the ChAdOx1 vector are induced by the first vaccination but do not prevent boosting and are not further increased by the second vaccination with either a 4-week or 8-week interval." https://t.co/P7DrGUjt2t

@yaquenous @OuestFrance Les élémednts de réponse sont ici. https://t.co/f9cctH2ecA On en reparle après

@guillaumemaill @OuestFrance @PrAlainFischer Toutes les infos ici https://t.co/f9cctH2ecA. On en reparle après.

@ProfTomCotter @andrew_croxford @annec_moore No, it's wild-type full-length codon-optimized SARS-CoV-2 spike protein See e.g. https://t.co/sIzuzqeSkf or https://t.co/1d5oIY7OUZ

@OAPym @Rosewind2007 Not sure. It is mentioned in this paper: https://t.co/lc9WRCoySQ

Oxford vaccine stimulates broad antibody and T cell functions https://t.co/1h8RqwMjIb https://t.co/fxSiVYoFFB https://t.co/pH7PyhzBbK https://t.co/YYj8DBr3hB

@AlexanderDent6 At first I was skeptical because immunologist were suggesting vector immunity played a part in the half/full protection but then I saw the phase 3 trial immunity data comparing half/full to full/full and immunity looks very similar b/w b…

@LJAkaar67 @conor64 The AZ vaccine has already passed a phase 1/2 trial, meaning that it is acknowledged by the FDA to be safe. FDA is waiting for the phase 3 to finish, which proves efficacy not safety https://t.co/BCKAjYtqmn

@musthafa4647 @HiyaleeM @Universityofoxf https://t.co/0sT2xoI3ss

@DatingaSociopat @markharden @belfastcityfan @BorisJohnson https://t.co/HenkHsUe9H

@JEANPie91114231 @gerard_larcher @franceinfo https://t.co/0WTKGyLaO1

https://t.co/KrgX9F9OEZ

@Muallimsays @WHO https://t.co/0sT2xoI3ss

@tickitiboo @katheross @theJeremyVine And the multi-dose data https://t.co/XMuxOjhEi4

@houndcl @PeterHotez @K_G_Andersen Curevac mRNA vaccine (CVnCoV) is the same protein as Pfizer. Therefore, for comparing mRNA, Ad-vector and subunit vaccines we'll have to guess that the FCS has a low impact. AstraZeneca protein is different https://t.…

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

RT @Tiki_taka888: @globalhlthtwit Phase I/II data of the Ox/AZ shows that the antibody response is boosted by the second dose, T-cell respo…

@globalhlthtwit Phase I/II data of the Ox/AZ shows that the antibody response is boosted by the second dose, T-cell response maxed after 1st dose. https://t.co/OEf1qA15mv

@cypherspace @janemerrick23 If they left it as the 12 week schedule for AZ then that would make be a pragmatic approach to limited vaccine supply, and this fits with approval. T-cell not boosted by second shot, but antibodies were https://t.co/OEf1qA15mv

RT @AskDrShashank: https://t.co/IESKguipMK

More data from the Oxford group vaccine 🦠🧬 Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine https://t.co/4AUGWLdACG

https://t.co/IESKguipMK

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Good news on #Covid19 vaccine - 2 doses boost antibody response #healthcare

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

https://t.co/RNwCQRcZyl

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2 trial participants. #COVID19 @OxfordVacGroup @ajpollard1 https://t.co/lxJ50hlssu

@KurtadikarKetan @andrew_croxford https://t.co/AS1LE3gfyS https://t.co/zMQ5KjrnDP

RT @PLMcCarthyMD: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses http…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https://t.co/qtJOBNUZFC

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Deux publications sur le vaccin d'AstraZeneca dans la revue Nature suggèrent une réponse immunitaire très complète après les injections, particulièrement si la seconde dose est une dose pleine, et non réduite de moitié. 1 ▶️https://t.co/oBlTcxXuTZ 2 ▶️htt…

@Jason86581520 @zev_dr @AntonAlberts @Jonathan_Witt @NickHudsonCT @mynameisjerm @RobHutchinson8 @denisrancourt @noa21sa @PanData19 @RobertKennedyJr I forgot this one: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces mul…

RT @mmw_lmw: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @Oxford…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @OxfordVacGroup @NatureMedicine https://t.co/tJPE8qfEd7 https://t.co/39S7A1vK9a

RT @mmw_lmw: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @Oxford…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https://t.co/qz6AOipyrv

RT @mmw_lmw: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @Oxford…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @OxfordVacGroup @NatureMedicine https://t.co/tJPE8qfEd7 https://t.co/K2PWe23WWN

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

RT @mmw_lmw: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @Oxford…

RT @MaenHouseh: الاوراق البحثية تنهال كالمطر! مثال: 5 اوراق هامة اليوم نشرت في اهم الدوريات 👇 سباق للنشر وتحدي للمتابعة والبقاء على اطلاع…

RT @mmw_lmw: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @Oxford…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | @OxfordVacGroup @NatureMedicine https://t.co/tJPE8qfEd7 https://t.co/D2a3HcVmal

RT @BertrandBio: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https://t.co/Cc8CNQ5QHy

and this https://t.co/VkRcxV05lZ The more options we have, the better. Inconcievable if you had said to most scientists 12 months ago that we would have 3 EUA vaccine candidates that pass Phase III trials within a year.

RT @EricTopol: 2 new @NatureMedicine reports for immune response to the @AstraZeneca @UniofOxford vaccine https://t.co/QpjkNPBFWc https://t…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https://t.co/ISWFqPn8qI https://t.co/ToiCJVWrAV - via Researcher (@ResearcherApp)

@1nationtory https://t.co/FwXRD9uusb

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine https://t.co/iLsLSxIZ7s

RT @JennerInstitute Two new papers on more detailed immunology of the Oxford-AZ vaccine: multifunctional Ab responses and T cell immunity https://t.co/W4JWrAbwaY #science #medicine

RT @zzz_as_zzz: スパイク蛋白だけのｍRNAワクチンでもIL-8が動いているので多分マクロファージ/単球も反応。二つ目の論文で気になるのが抗体の出方と効き方。単球と好中球のFc受容体との絡み方も調べている点は好感が持てますが、重症例と似た様な反応を示すのが？…

@AlistairHaimes Another peer review, the Oxford AZ vaccine is looking good on all fronts, it should be fast tracked now. https://t.co/J3RoIhXKUU

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. by Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, Verheul M……

NJs/ Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.https://t.co/EdYyeB7JLW

アストラゼネカのワクチンは、アデノウイルスという膜の付いてないものを利用している。でも、中に入っているmRNAでスパイクが作られると、それは、細胞膜上に移動。初回と二回目の間を56日にした場合、NK細胞との反応性は重症例と同じくらい。 28日だと、少し低め。 http…

Un court thread de @Fraslin rapportant une publication dans Nature qui tend à montrer que le vaccin d'AstraZeneca ne poserait pas de problème chez les personnes ayant déjà été infectées par la covid. #ApresJ20 #longcovid https://t.co/bdTTuNn3of

More data on Oxford/AstraZenica vaccine. Published in Nature. Available as 28-page PDF: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses https://t.co/tLsKmMxJLS

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine https://t.co/5kYPmRi6hA

RT @Fraslin: Étude du vaccin Oxford: «Pas d'association entre la réactogénicité et la présence ou l'absence d'anticorps contre le SRAS-CoV-…

Étude du vaccin Oxford: «Pas d'association entre la réactogénicité et la présence ou l'absence d'anticorps contre le SRAS-CoV-2 ou ChAdOx1 au moment de la vaccination. Il s'agit d'une découverte importante https://t.co/fhNTJb6hus

RT @EricTopol: 2 new @NatureMedicine reports for immune response to the @AstraZeneca @UniofOxford vaccine https://t.co/QpjkNPBFWc https://t…

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Very pleased to be able to share this!

RT @JennerInstitute: Two new papers on more detailed immunology of the Oxford-AZ vaccine: multifunctional Ab responses and T cell immunity…

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Phase 1/2 trial of #SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (#Oxford #AstraZeneca trial): https://t.co/4zv8G1BQcS

RT @NatureMedicine: Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2…

Two doses of the coronavirus disease 2019 #vaccine #ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2 trial participants. #COVID19 @OxfordVacGroup @ajpollard1 https://t.co/JKNMTVJBNy

RT @EricTopol: 2 new @NatureMedicine reports for immune response to the @AstraZeneca @UniofOxford vaccine https://t.co/QpjkNPBFWc https://t…

RT @Dr_SCT: Special thanks to @TheHawk_12 and @JackMellors2 for working up the SARS-CoV-2 antibody-dependent complement activation assay h…

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

About this Attention Score

Mentioned by

Readers on